November 2, 2022 02:44 PM EDT
Pharma
FDA+
Manufacturing

FDA warn­ing let­ters de­tail is­sues for man­u­fac­tur­ing sites in the US and In­dia

Tyler Patchen

News Reporter

The FDA this week re­leased new warn­ing let­ters for drug man­u­fac­tur­ers in the US and In­dia fol­low­ing the dis­cov­ery of sev­er­al qual­i­ty is­sues.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times